Primary Outcomes

Measure: Change from baseline in 24-hour cough count (measured by cough recording digital wearable monitoring device) after 12 weeks of intervention

Time: From baseline up to 12 weeks

---

Secondary Outcomes

Measure: Percentage of participants with a ≥30% reduction from baseline in 24-hour cough count after 12 weeks of intervention (measured by cough recording digital wearable monitoring device)

Time: From baseline up to 12 weeks

---

Measure: Change from baseline in 24-hour cough count after 2, 4, and 8 weeks of intervention (measured by cough recording digital wearable monitoring device)

Time: From baseline up to 2 weeks, 4 weeks and 8 weeks

---

Measure: Change from baseline in awake cough frequency per hour after 2, 4, 8 and 12 weeks of intervention (measured by cough recording digital wearable monitoring device)

Time: From baseline up to 2 weeks, 4 weeks, 8 weeks and 12 weeks

---

Measure: Change from baseline in cough related quality of life (measured by Leicester Cough Questionnaire [LCQ]) after 12 weeks of intervention

Time: From baseline up to 12 weeks

---

Measure: Change from baseline in cough severity after 12 weeks of intervention (measured by Cough Severity Visual Analogue Scale [VAS])

Time: From baseline up to 12 weeks

---

Measure: Percentage of participants with a ≥30 scale units reduction from baseline after 12 weeks of intervention (measured by cough Severity VAS)

Time: From baseline up to 12 weeks

---

Measure: Percentage of participants with a ≥1.3-point increase from baseline after 12 weeks of intervention (measured with LCQ Total Score)

Time: From baseline up to 12 weeks

---

Measure: Frequency and associated severity of treatment-emergent adverse events (TEAEs)

Time: From the start of study intervention administration until 14 days after the last study medication intake

---